A previous randomized trial of sevelamer carbonate measured levels of FGF23 and α-klotho in patients with non-dialysis-dependent CKD; it did not show any treatment effects on the levels of i-FGF23, c-FGF23, or α-klotho in patients for whom serum P did not significantly change [27]. Here, FGF23 is linked to chronic kidney disease.